S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI

Biophytis (BPTS) Competitors

$0.29
-0.04 (-12.10%)
(As of 04/16/2024 ET)

BPTS vs. KA, SNGX, YMTX, THAR, LIPO, CING, EVOK, ARTL, KTRA, and XCUR

Should you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Kineta (KA), Soligenix (SNGX), Yumanity Therapeutics (YMTX), Tharimmune (THAR), Lipella Pharmaceuticals (LIPO), Cingulate (CING), Evoke Pharma (EVOK), Artelo Biosciences (ARTL), Kintara Therapeutics (KTRA), and Exicure (XCUR). These companies are all part of the "pharmaceutical preparations" industry.

Biophytis vs.

Kineta (NASDAQ:KA) and Biophytis (NASDAQ:BPTS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking.

30.3% of Kineta shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 29.8% of Kineta shares are owned by insiders. Comparatively, 3.7% of Biophytis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kineta presently has a consensus target price of $8.00, indicating a potential upside of 1,567.71%. Biophytis has a consensus target price of $15.00, indicating a potential upside of 5,062.62%. Given Kineta's higher possible upside, analysts clearly believe Biophytis is more favorable than Kineta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kineta
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Biophytis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Kineta has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Biophytis has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.

Kineta's return on equity of 0.00% beat Biophytis' return on equity.

Company Net Margins Return on Equity Return on Assets
KinetaN/A -453.89% -118.90%
Biophytis N/A N/A N/A

Biophytis received 3 more outperform votes than Kineta when rated by MarketBeat users.

CompanyUnderperformOutperform
KinetaOutperform Votes
3
100.00%
Underperform Votes
No Votes
BiophytisOutperform Votes
6
100.00%
Underperform Votes
No Votes

Kineta has higher revenue and earnings than Biophytis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kineta$5.44M0.97-$14.10M-$1.38-0.35
BiophytisN/AN/A-$18.43MN/AN/A

In the previous week, Biophytis had 1 more articles in the media than Kineta. MarketBeat recorded 2 mentions for Biophytis and 1 mentions for Kineta. Biophytis' average media sentiment score of 0.96 beat Kineta's score of 0.08 indicating that Kineta is being referred to more favorably in the media.

Company Overall Sentiment
Kineta Positive
Biophytis Neutral

Summary

Biophytis beats Kineta on 6 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPTS vs. The Competition

MetricBiophytisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.08M$6.53B$4.71B$7.48B
Dividend YieldN/A3.10%5.48%3.96%
P/E RatioN/A12.63234.2716.90
Price / SalesN/A315.212,538.5787.71
Price / CashN/A20.2533.4028.10
Price / Book-0.685.414.664.27
Net Income-$18.43M$144.02M$100.35M$210.87M
7 Day Performance-30.39%-6.25%-4.95%-5.12%
1 Month Performance-39.27%-5.65%-3.63%-2.67%
1 Year Performance-92.39%1.11%12.57%6.50%

Biophytis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KA
Kineta
3.1774 of 5 stars
$0.43
-20.4%
$8.00
+1,760.5%
-85.0%$4.71M$5.44M-0.3111Gap Up
High Trading Volume
SNGX
Soligenix
0.3468 of 5 stars
$0.47
-4.1%
$3.00
+545.0%
-69.9%$4.90M$840,000.00-0.5213
YMTX
Yumanity Therapeutics
0 of 5 stars
$0.43
-20.4%
N/A-85.0%$4.67M$4.84M-0.1440Gap Up
High Trading Volume
THAR
Tharimmune
0 of 5 stars
$0.42
-4.5%
N/AN/A$4.93MN/A-0.032News Coverage
LIPO
Lipella Pharmaceuticals
3.7728 of 5 stars
$0.73
+4.3%
N/A-60.6%$4.56M$449,617.000.005Gap Up
High Trading Volume
CING
Cingulate
2.3405 of 5 stars
$1.01
flat
$8.00
+692.1%
-95.9%$5.06MN/A-0.0315News Coverage
EVOK
Evoke Pharma
0 of 5 stars
$0.53
-5.4%
N/A-75.8%$4.49M$5.18M-0.234
ARTL
Artelo Biosciences
3.1355 of 5 stars
$1.58
+0.6%
$5.00
+216.5%
-44.7%$5.10MN/A-0.505Positive News
KTRA
Kintara Therapeutics
0 of 5 stars
$0.13
flat
N/A-96.2%$5.14MN/A-0.022
XCUR
Exicure
2.9654 of 5 stars
$0.60
+3.4%
N/A-39.1%$5.19M$28.83M0.367Gap Down

Related Companies and Tools

This page (NASDAQ:BPTS) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners